Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 241 AL 255

Changes in brain amyloid-β accumulation after donepezil administration

Ishibashi K, Miura Y, Wagatsuma K, Ishiwata K, Ishii K.

J Clin Neurosci. 2017 Nov;45:328-329. doi: 10.1016/j.jocn.2017.08.025. Epub 2017 Aug 31.

Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease

Kim SH, Kandiah N, Hsu JL, Suthisisang C, Udommongkol C, Dash A.

Br J Pharmacol. 2017 Dec;174(23):4224-4232. doi: 10.1111/bph.14030. Epub 2017 Oct 29.

Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease

Cavedo E, Grothe MJ, Colliot O, Lista S, Chupin M, Dormont D, Houot M, Lehéricy S, Teipel S, Dubois B, Hampel H; Hippocampus Study Group.

Sci Rep. 2017 Sep 15;7(1):11706. doi: 10.1038/s41598-017-09780-3.

Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological Perspectives

Kamal MA, Greig NH.

Curr Alzheimer Res. 2017;14(11):1138-1139. doi: 10.2174/156720501411171006122827.

Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATIE-AD Data

Ozawa C, Roberts R, Yoshida K, Suzuki T, Lebowitz B, Reeves S, Howard R, Abe T, Mimura M, Uchida H.

J Clin Psychiatry. 2017 Nov/Dec;78(9):e1204-e1210. doi: 10.4088/JCP.17m11461.

[Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain]

Watanabe H.

Yakugaku Zasshi. 2017;137(11):1361-1365. doi: 10.1248/yakushi.17-00156.

Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease

Chakravarthy M, Chen S, Dodd PR, Veedu RN.

Theranostics. 2017 Sep 5;7(16):3933-3947. doi: 10.7150/thno.21529. eCollection 2017.

Developing Disease-Modifying Treatments in Alzheimer's Disease - A Perspective from Roche and Genentech

Doody R.

J Prev Alzheimers Dis. 2017;4(4):264-272. doi: 10.14283/jpad.2017.40.

Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential

Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M.

J Prev Alzheimers Dis. 2017;4(3):149-156. doi: 10.14283/jpad.2017.26.

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease

Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators.

Alzheimers Res Ther. 2017 Dec 8;9(1):95. doi: 10.1186/s13195-017-0318-y.

Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment

Gejl M, Brock B, Egefjord L, Vang K, Rungby J, Gjedde A.

Sci Rep. 2017 Dec 13;7(1):17490. doi: 10.1038/s41598-017-17718-y.

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

Wu XL, Piña-Crespo J, Zhang YW, Chen XC, Xu HX.

Chin Med J (Engl). 2017 Dec 20;130(24):2978-2990. doi: 10.4103/0366-6999.220313.

The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial

Li M, Lyu JH, Zhang Y, Gao ML, Li WJ, Ma X.

Medicine (Baltimore). 2017 Dec;96(51):e9381. doi: 10.1097/MD.0000000000009381.

Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series

Devanand DP, Pelton GH, D'Antonio K, Strickler JG, Kreisl WC, Noble J, Marder K, Skomorowsky A, Huey ED.

Alzheimer Dis Assoc Disord. 2017 Jan-Mar;31(1):73-75. doi: 10.1097/WAD.0000000000000161.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias